Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Zaremba

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
International Journal of Molecular Sciences|March 25, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint InhibitionLuca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseFlorentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2021
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyAnne Zaremba, Georg Lodde, Rajmohan Murali, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeEleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
International Journal of Cancer|June 23, 2022
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
International Journal of Molecular Sciences|March 25, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint InhibitionLuca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseFlorentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2021
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyAnne Zaremba, Georg Lodde, Rajmohan Murali, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeEleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
International Journal of Cancer|June 23, 2022
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Pageof 5